. 2015 Aug 21;10(8):e0136080. doi: 10.1371/journal.pone.0136080

Table 1. IC₅₀ and relative resistance (RR) values measured in response to etoposide, cisplatin and doxorubicin treatment of Caco-2 cells stably expressing non-target shRNA (shNT) or shMRP2.

	shNT	shMRP2
	IC₅₀ (μM)	IC₅₀ (μM)	RR
Etoposide	328.2	108.5	0.33
Cisplatin	87.8	31.8	0.36
Doxorubicin	32.8	13.1	0.40

Caco-2 cells stably expressing shNT or shMRP2 (#305) were incubated with the cytotoxic drugs for 84 h. Sensitivity to the anti-cancer drug was determined by the MTT cell viability assay. Dose-response curves were fitted to the data to determine the toxicity (IC₅₀ value) of the drugs. Inhibition of human shMRP2 expression reduced the resistance of Caco-2 cells to etoposide, cisplatin and doxorubicin compared to control cells.

Table 1. IC50 and relative resistance (RR) values measured in response to etoposide, cisplatin and doxorubicin treatment of Caco-2 cells stably expressing non-target shRNA (shNT) or shMRP2.

Table 1. IC₅₀ and relative resistance (RR) values measured in response to etoposide, cisplatin and doxorubicin treatment of Caco-2 cells stably expressing non-target shRNA (shNT) or shMRP2.